In this issue:
Switching from originator to biosimilar infliximab in SpA
Meta-analysis: comparing biologics for mucosal healing in CD and UC
Pregnancy influences pharmacokinetics of infliximab in IBD
Response to ustekinumab in medically refractory CD
Infliximab not associated with malignancy in paediatric IBD
Tofacitinib for induction and maintenance of CD
Peficitinib in rheumatoid arthritis
Please login below to download this issue (PDF)